AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
AEZS has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating on shares of AEterna Zentaris in a research report on Thursday, January 17th. ValuEngine raised shares of AEterna Zentaris from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd. Finally, Maxim Group set a $2.00 price objective on shares of AEterna Zentaris and gave the company a “buy” rating in a research report on Thursday, December 20th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $2.67.
Large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its position in AEterna Zentaris by 27.2% in the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 9,640 shares in the last quarter. Virtu Financial LLC acquired a new position in AEterna Zentaris in the third quarter worth about $101,000. O Shaughnessy Asset Management LLC acquired a new position in AEterna Zentaris in the fourth quarter worth about $66,000. Finally, Jane Street Group LLC acquired a new position in AEterna Zentaris in the fourth quarter worth about $30,000. 15.31% of the stock is owned by hedge funds and other institutional investors.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Read More: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.